Results 11 to 20 of about 541,695 (230)

A one-mutation mathematical model can explain the age incidence of acute myeloid leukemia with mutated nucleophosmin (NPM1) [PDF]

Haematologica, 2008
Acute myeloid leukemia with mutated NPM1 gene and aberrant cytoplasmic expression of nucleophosmin (NPMc+ acute myeloid leukemia) shows distinctive biological and clinical features.
Arcangelo Liso, Filippo Castiglione, Antonio Cappuccio, Fabrizio Stracci, Richard F. Schlenk, Sergio Amadori, Christian Thiede, Susanne Schnittger, Peter J.M. Valk, Konstanze Döhner, Massimo F. Martelli, Markus Schaich, Jürgen Krauter, Arnold Ganser, Maria P. Martelli, Niccolò Bolli, Bob Löwenberg, Torsten Haferlach, Gerhard Ehninger, Franco Mandelli, Hartmut Döhner, Franziska Michor, Brunangelo Falini   +22 more
doaj   +4 more sources

The polo-like kinase 1 (PLK1) inhibitor NMS-P937 is effective in a new model of disseminated primary CD56+ acute monoblastic leukaemia [PDF]

, 2013
CD56 is expressed in 15–20% of acute myeloid leukaemias (AML) and is associated with extramedullary diffusion, multidrug resistance and poor prognosis.
A Blair, A Cesano, A Vilas-Zornoza, AG Renner, Alessandro Rambaldi, Alessia Casolaro, Alice Pezzoni, B Löwenberg, B Valsasina, Barbara Valsasina, C McInnes, Clara Albanese, D Raspadori, E Di Bona, E Estey, E Radaelli, EM Lee, Enrico Pesenti, F Ravandi, FR Appelbaum, Francesco Bertolini, Francesco Marchesi, G Tsykunova, Gemma Texido, Gianni Cazzaniga, H Chang, I Beria, J Delgado, J Golay, J Suela, J Zuber, Josee Golay, JR Novontny, JW Rocco, K Strebhardt, M Bardini, Marco Losa, Martino Introna, MJ Walter, MR Baer, Nadia Amboldi, PA Greif, R Giavazzi, Rachele Alzani, Roberta Ceruti, S Gattenloehner, Sabrina Cribioli, Silvia Bungaro, T Berg, T Ikezoe, T Lapidot, TJ Ley, U Cucchi, Ursula Giussani, Veronica Patton, Z Li   +55 more
core   +6 more sources

SnapShot: Acute Myeloid Leukemia [PDF]

Cancer Cell, 2012
20%-25% (28%-35%); High blast count; Poor prognosisespecially in cases with high mutant to WT allelic ratio5%-7% (10%-14%); Prognostic impact remains controversial10% (9%-14%); Enriched in CBF AML; Prognosis ...
Ghulam J. Mufti, Chi Wai Eric So, Bernd B. Zeisig, Austin G. Kulasekararaj   +3 more
openaire   +2 more sources

Cytoplasmic mutated nucleophosmin is stable in primary leukemic cells and in a xenotransplant model of NPMc+ acute myeloid leukemia in SCID mice

Haematologica, 2008
We investigated the NPM1 mutation status or subcellular expression of NPM protein (nuclear vs. aberrant cytoplasmic) at diagnosis and relapse in 125 patients with acute myeloid leukemia from Italy and Germany.
Brunangelo Falini, Maria Paola Martelli, Cristina Mecucci, Arcangelo Liso, Niccolò Bolli, Barbara Bigerna, Alessandra Pucciarini, Stefano Pileri, Giovanna Meloni, Massimo F. Martelli, Torsten Haferlach, Susanne Schnittger   +11 more
doaj   +1 more source

Acute Promyelocytic Leukemia Presenting With a Myeloid Sarcoma of the Spine: A Case Report and Literature Review

Frontiers in Oncology, 2022
Myeloid sarcoma is a rare extramedullary tumor of immature myeloid cells. Certain known acute myeloid leukemia cytogenetic abnormalities, in particular t(8,21), has been associated with a higher incidence.
Xuemei Shu, Qiuling Wu, Tao Guo, Hua Yin, Jingdi Liu   +4 more
doaj   +1 more source

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.

New England Journal of Medicine, 2020
BACKGROUND Older patients with acute myeloid leukemia (AML) have a dismal prognosis, even after treatment with a hypomethylating agent. Azacitidine added to venetoclax had promising efficacy in a previous phase 1b study.
C. Dinardo, B. Jonas, V. Pullarkat, M. Thirman, Jacqueline S. Garcia, A. Wei, M. Konopleva, H. Döhner, A. Letai, P. Fenaux, E. Koller, V. Havelange, B. Leber, J. Esteve, Jianxiang Wang, V. Pejsa, R. Hájek, K. Porkka, Á. Illés, D. Lavie, R. Lemoli, Kazuhito Yamamoto, S. Yoon, J. Jang, S. Yeh, M. Turgut, W. Hong, Ying Zhou, J. Potluri, K. Pratz   +29 more
semanticscholar   +1 more source

Advances in acute myeloid leukemia

British medical journal, 2021
Acute myeloid leukemia (AML) is an uncommon but potentially catastrophic diagnosis with historically high mortality rates. The standard of care treatment remained unchanged for decades; however, recent discoveries of molecular drivers of leukemogenesis ...
L. Newell, R. Cook
semanticscholar   +1 more source

RUNX oncoproteins and miRNA networks [PDF]

, 2017
News on: An AML1-ETO/miR-29b-1 regulatory circuit modulates phenotypic properties of acute myeloid leukemia cells by Zaidi et al. Oncotarget. 2017; 8:39994-40005.
Borland, Gillian, Hay, Jodie, Neil, James C.   +2 more
core   +1 more source

Uncommon CD markers in acute myeloid leukemia

Bangabandhu Sheikh Mujib Medical University Journal, 2018
This study was done to assess the unusual CD expression in 100 cases of acute myeloid leukemia from October 2016 to April 2018. The age limit was from 3 to 50 years.
Azad Abul Kalam, Md. Rafiquzzaman Khan, A. B. M. Hassan Habib, Masuda Begum   +3 more
doaj   +1 more source

Unlocking the potential of anti-CD33 therapy in adult and childhood acute myeloid leukaemia [PDF]

, 2017
Acute Myeloid Leukaemia (AML) develops when there is a block in differentiation and uncontrolled proliferation of myeloid precursors, resulting in bone marrow failure.
Gibson, Brenda E.S., Harrison, Christine J., Keeshan, Karen, Laing, Alison A.   +3 more
core   +1 more source